According to findings from a long term study, men with prostate cancer (PCa) who are treated with degarelix (a newly approved gonadotropin-releasing hormone receptor (GnRH) blocker) have a lower risk of PSA failure or death compared with those treated with leuprolide. […]
There is a constant debate between both oncologist and advocates about the value and safety of 5-alpha-reductase inhibitors (Proscar and Avodart) both in the early treatment and later treatment of men with prostate cancer. In fact, I have had an on-going private debate with one very knowledgeable educator advocate over this issue. I often have [...]
Data from the recent ASCO conference on a phase II study of cabozantinib (XL184) in patients with advanced solid tumors, including prostate cancer, demonstrates that the investigational treatment has activity in both bone and soft tissue. This study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including [...]
My very dear friend Fred who is a 20+ year prostate cancer warrior recorded this video. He has been on chemotherapy this past year. Fred is an activist who has been fighting on behalf of all of us. Thank you, Fred. I just thought I would share his video at: See my friend Fred Joel [...]
YOUR DEADLINE: WEDNESDAY, JUNE 22, 2011 On Wednesday and Thursday, the House will meet at 10:00 a.m. for Morning Hour debate and 12:00 p.m. for legislative business. H.R. 2219, the Department of Defense Appropriations Act, 2012 (Rep. Young (FL) - Appropriations), has been placed on the House calendar for then. As part of H.R. 2219 [...]